Today, on 7 December 2018, first day of trading occurred in the IPO of Q-linea on Nasdaq Stockholm. The IPO attracted strong interest from institutional investors as well as the general public in Sweden and was substantially over-subscribed.
Q-linea AB is a diagnostics company focused on developing and delivering solutions for healthcare providers, enabling them to accurately diagnose and treat infectious diseases in the shortest possible time. Q-linea’s core product, ASTar™, is a system for rapid and automatic determination of the most effective antibiotic treatment against infectious diseases. The
Carnegie Investment Bank AB (publ) was Sole Global Coordinator and Bookrunner and Redeye AB was Co-lead Manager (together “Managers”). Baker McKenzie acted as legal advisor to the Managers as to Swedish and US law. Baker McKenzie's team mainly consisted of Joakim Falkner, Johanna Flink, Ian Gulam, Stefan Balazs from the firm’s Stockholm office, Els Janssen from Abu Dhabi, Adam Farlow and Charles Farnsworth from London and Kai Kramer, Rodney Read and Patrick Renckly from Houston.